SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-057861
Filing Date
2022-02-28
Accepted
2022-02-28 16:06:36
Documents
14
Period of Report
2022-02-28
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d214686d8k.htm   iXBRL 8-K 24295
2 EX-99.1 d214686dex991.htm EX-99.1 88716
6 GRAPHIC g214686g0226100432171.jpg GRAPHIC 4581
  Complete submission text file 0001193125-22-057861.txt   251145

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rvmd-20220228.xsd EX-101.SCH 2892
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvmd-20220228_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvmd-20220228_pre.xml EX-101.PRE 10836
8 EXTRACTED XBRL INSTANCE DOCUMENT d214686d8k_htm.xml XML 3264
Mailing Address 700 SAGINAW DR REDWOOD CITY CA 94063
Business Address 700 SAGINAW DR REDWOOD CITY CA 94063 415-766-3638
Revolution Medicines, Inc. (Filer) CIK: 0001628171 (see all company filings)

IRS No.: 472029180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39219 | Film No.: 22689350
SIC: 2836 Biological Products, (No Diagnostic Substances)